On November 23, 2017, at 08:00 CET, Wilson Therapeutics will publish its interim report for the third quarter 2017. All interested parties are invited to participate in a web-cast telephone conference, which will include a presentation, on the same day at 10:00 CET. The event will be hosted by Wilson Therapeutics’ CEO Jonas Hansson and CFO Anders Martin-Löf, and the presentation will be held in English.
How to participate
The live webcast and a recorded on-demand version including the presentation material will be accessible at: https://tv.streamfabriken.com/wilson-therapeutics-q3-2017 . Questions can be asked in writing via the webcast or verbally via the conference call.
To participate in the conference call, please call one of the following numbers:
- SE: +46 8 566 426 90
- UK: +44 203 008 9801
- US: +1 855 753 2235
The presentation material will also be published before the conference starts on Wilson Therapeutics’ website www.wilsontherapeutics.com under Media & Investors/ Presentations. The webcast, and later the recorded version of the webcast and the conference call, will also be accessible via Wilson Therapeutics’ website.
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information.
For further information contact:
Anders Martin-Löf, CFO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: [email protected]
Wilson Therapeutics AB (publ)
Corp. Reg. No. 556893-0357
SE-111 43 Stockholm
Powered by WPeMatico